Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for eXoZymes Inc. (EXOZ : NSDQ)
 
 • Company Description   
Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Number of Employees: 31

 
 • Price / Volume Information   
Yesterday's Closing Price: $14.34 Daily Weekly Monthly
20 Day Moving Average: 2,461 shares
Shares Outstanding: 8.39 (millions)
Market Capitalization: $120.27 (millions)
Beta:
52 Week High: $23.99
52 Week Low: $8.86
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.56% -13.71%
12 Week 4.29% 1.31%
Year To Date -13.09% -17.87%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
750 Royal Oaks Drive Suite 106
-
MONROVIA,CA 91016
USA
ph: 626-415-1488
fax: -
press@exozymes.com http://www.exozymes.com
 
 • General Corporate Information   
Officers
Michael Heltzen - Chief Executive Officer and President
Christopher A. Marlett - Chairman
Fouad Nawaz - Vice President; Finance
Anthony DiGiandomenico - Director
James U. Bowie - Director

Peer Information
eXoZymes Inc. (CORR.)
eXoZymes Inc. (RSPI)
eXoZymes Inc. (CGXP)
eXoZymes Inc. (BGEN)
eXoZymes Inc. (GTBP)
eXoZymes Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 461874109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/30/26
Share - Related Items
Shares Outstanding: 8.39
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $120.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/30/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 22.38
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 3.57%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/25 - -104.58
06/30/25 - -134.50
03/31/25 - -170.91
ROA
09/30/25 - -79.55
06/30/25 - -81.63
03/31/25 - -95.43
Current Ratio
09/30/25 - 4.53
06/30/25 - 6.19
03/31/25 - 6.52
Quick Ratio
09/30/25 - 4.53
06/30/25 - 6.19
03/31/25 - 6.52
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Book Value
09/30/25 - 0.64
06/30/25 - 0.86
03/31/25 - 1.06
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.01
06/30/25 - 0.01
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - 1.41
06/30/25 - 1.19
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©